Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants

Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants

Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are ava...

Full description

Bibliographic Details
Main Author: Belfrage, Anna Karin
Format: Doctoral Thesis
Language:English
Published: Uppsala universitet, Avdelningen för organisk farmaceutisk kemi 2015
Subjects:
hepatitis C virus
HCV
NS3 protease inhibitors
structure-activity relationship
2(1H)-pyrazinone
quinazoline
resistance
Pd catalysis
Online Access:http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-243317
http://nbn-resolving.de/urn:isbn:978-91-554-9166-6

Internet

http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-243317
http://nbn-resolving.de/urn:isbn:978-91-554-9166-6

Similar Items